Our cutting-edge research and development strategy focuses on developing breakthrough therapeutics that transform lives.
Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system
BO-112 is a therapy designed to stimulate the immune system and enhance anti-tumor responses. Administered via intratumoral injection, BO-112 aims to convert immunologically «cold» tumors into «hot» tumors, thereby improving the efficacy of other immunotherapies.
